Elizabeth Masson-Hurlburt
Corporate Officer/Principal en CORMEDIX INC. .
Fortuna: 235 610 $ al 30/04/2024
Cargos activos de Elizabeth Masson-Hurlburt
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - | - |
| Director Técnico/Científico/I+D | 01/03/2018 | - |
Historial de carrera de Elizabeth Masson-Hurlburt
Antiguos cargos conocidos de Elizabeth Masson-Hurlburt.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/08/2016 | 01/03/2018 |
Formación de Elizabeth Masson-Hurlburt.
| Bay Path College | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
